Kodiak Sciences Inc Total Liabilities
Kodiak Sciences Inc total liabilities. Based on the latest financial reports, Kodiak Sciences Inc (KOD) has total liabilities worth $195.72 Million USD as of June 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Check asset resilience ratio of Kodiak Sciences Inc to evaluate the company's liquid asset resilience ratio.
Total Liabilities of Kodiak Sciences Inc (2016–2025)
Total liabilities of Kodiak Sciences Inc from 2016 to 2025. This chart illustrates how Kodiak Sciences Inc's total liabilities have evolved over time, based on quarterly financial data. Explore Kodiak Sciences Inc long-term investment allocation to see how much of total assets are deployed in long-term investments.
Kodiak Sciences Inc Competitors by Total Liabilities
The table below lists competitors of Kodiak Sciences Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Schaeffler India Limited
NSE:SCHAEFFLER
|
India | Rs23.65 Billion |
|
Reinet Investments S.C.A
AS:REINA
|
Netherlands | €2.00 Million |
|
Pilbara Minerals Ltd
AU:PLS
|
Australia | AU$1.13 Billion |
|
Amneal Pharmaceuticals, Inc. Class A Common Stock
NASDAQ:AMRX
|
USA | $3.66 Billion |
|
Hyundai Rotem Co
KO:064350
|
Korea | ₩5.70 Trillion |
|
The People's Insurance Company (Group) of China Limited
F:PIR
|
Germany | €1.61 Trillion |
|
Mirum Pharmaceuticals Inc
NASDAQ:MIRM
|
USA | $648.42 Million |
Liability Composition Analysis (2016–2025)
This chart breaks down Kodiak Sciences Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see Kodiak Sciences Inc total assets.
Liquidity & Leverage Metrics
Kodiak Sciences Inc Total Liabilities Ratios Explained
Kodiak Sciences Inc total liabilities ratios compare its liabilities with its current assets, cash and shareholder equity.
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 2.49 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 3.20 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.76 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Kodiak Sciences Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Kodiak Sciences Inc (2016–2025)
The table below shows the annual total liabilities of Kodiak Sciences Inc from 2016 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | $194.15 Million | +4.78% |
| 2024-12-31 | $185.29 Million | -13.25% |
| 2023-12-31 | $213.59 Million | -7.32% |
| 2022-12-31 | $230.46 Million | -4.33% |
| 2021-12-31 | $240.90 Million | +16.60% |
| 2020-12-31 | $206.60 Million | +1429.55% |
| 2019-12-31 | $13.51 Million | +152.18% |
| 2018-12-31 | $5.36 Million | -92.56% |
| 2017-12-31 | $71.98 Million | +35.31% |
| 2016-12-31 | $53.20 Million | -- |
About Kodiak Sciences Inc
Kodiak Sciences Inc., a clinical stage biopharmaceutical company, engages in the research, development, and commercialization of therapeutics to treat retinal diseases. Its lead product candidate is tarcocimab tedromer (KSI-301), an anti-vascular endothelial growth factor (VEGF) antibody biopolymer that has complete Phase 3 clinical study to treat high prevalence retinal vascular diseases; and in… Read more